A DOUBLE-BLIND, PLACEBO-CONTROLLED COMPARISON OF SODIUM CROMOGLYCATE AND KETOTIFEN IN THE TREATMENT OF CHILDHOOD ASTHMA

We compared three treatments: sodium cromoglycate 5 mg aerosol and pla cebo syrup (39 patients), placebo aerosol and ketotifen syrup (39 pati ents), and placebo aerosol and syrup (36 patients). The patients (mean age 11.7 years) had mostly allergic, moderately severe asthma. Treatm ents were added to current therapy (mostly bronchodilators only) for 3 months. Aerosols were taken four times daily and syrups twice daily. The following results were significant at a level of 5%. At the final clinic visit, the changes from baseline in lung function favored sodiu m cromoglycate over the other treatments. During month 3, sodium cromo glycate was superior to ketotifen for night symptoms, morning tightnes s, daytime symptoms, and cough. Bronchodilator use decreased more with sodium cromoglycate than ketotifen. Patients' and clinicians' overall opinions of treatment effectiveness favored sodium cromoglycate over ketotifen and placebo. In these patients, sodium cromoglycate was both effective and superior to ketotifen.